Find Recurrent Clinical Trials in Columbus, Ohio – 80 Enrolling Now

Showing 1–20 of 80 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more

National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377

Recruiting

Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more

National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739

Recruiting

Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814

Recruiting

Phase 1Phase 2

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia

National Cancer Institute (NCI)84 enrolled4 locationsNCT06965114

Recruiting

Phase 3

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Stage IV Lung Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Lung Small Cell Carcinoma+1 more

NRG Oncology200 enrolled227 locationsNCT04804644

Recruiting

Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more

National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060

Recruiting

Phase 2

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant

National Cancer Institute (NCI)20 enrolled21 locationsNCT06311227

Recruiting

Phase 1

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal AdenocarcinomaRecurrent Colorectal Adenocarcinoma+1 more

National Cancer Institute (NCI)30 enrolled15 locationsNCT06102902

Recruiting

Phase 1Phase 2

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more

Immatics US, Inc.375 enrolled21 locationsNCT03686124

Recruiting

Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more

National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594

Recruiting

Phase 2

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8+3 more

Dwight Owen56 enrolled5 locationsNCT04919382

Recruiting

Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more

ECOG-ACRIN Cancer Research Group804 enrolled303 locationsNCT04423211

Recruiting

Phase 1

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma

Dwight Owen24 enrolled1 locationNCT06616623

Recruiting

Phase 1

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+2 more

Dwight Owen30 enrolled1 locationNCT05234307

Recruiting

Phase 2Phase 3

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma

SWOG Cancer Research Network378 enrolled361 locationsNCT06616584

Recruiting

Phase 2

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma

SWOG Cancer Research Network56 enrolled267 locationsNCT06031688

Recruiting

Phase 2

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma

SWOG Cancer Research Network66 enrolled448 locationsNCT05642572

Recruiting

Phase 2

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer

Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285

Recruiting

Phase 2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recurrent B Acute Lymphoblastic LeukemiaDown Syndrome

National Cancer Institute (NCI)461 enrolled215 locationsNCT04546399

Recurrent Clinical Trials in Columbus, Ohio

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)